Insights from transgenic mouse models of ERBB2-induced breast cancer

Josie Ursini-Siegel, Babette Schade, Robert Cardiff, William J. Muller

Research output: Contribution to journalReview articlepeer-review

198 Scopus citations


One-third of patients with breast cancer overexpress the ERBB2 receptor tyrosine kinase, which is associated not only with a more aggressive phenotype but also reduced responsiveness to hormonal therapies. Over the past two decades, many ERBB2 mouse models for breast cancer have conclusively shown that this receptor has a causal role in breast cancer development. These mouse models have also enabled the mechanisms controlling tumour growth, angiogenesis, metastasis, dormancy and recurrence in ERBB2-positive breast cancer to be elucidated. In addition, a mouse model has recently been described that accurately recapitulates many of the hallmarks associated with the early stages of the human disease.

Original languageEnglish (US)
Pages (from-to)389-397
Number of pages9
JournalNature Reviews Cancer
Issue number5
StatePublished - May 1 2007

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Insights from transgenic mouse models of ERBB2-induced breast cancer'. Together they form a unique fingerprint.

Cite this